

**For Immediate Release**

**Contact:** Dennis F. Willson  
President & CEO  
Cytokine PharmaSciences, Inc.  
(610) 687-1776 ext. 211

**CAMERON MACDONALD APPOINTED MANAGING DIRECTOR OF CONTROLLED THERAPEUTICS (SCOTLAND) LIMITED**

**KING OF PRUSSIA, PA, USA and East Kilbride, Scotland, March 29, 2007** - Cytokine PharmaSciences, Inc. (CPSI) today announced that Cameron Macdonald, Ph.D. will become the Managing Director of the Company's wholly owned operating subsidiary, Controlled Therapeutics (Scotland) Limited (CTS). Dr. Macdonald will also be named a Vice President of CPSI.

Dr. Macdonald earned a degree in biochemistry with first class honors from Strathclyde University. He later received his doctorate from the Department of Materia Medica at the University of Glasgow. Dr. Macdonald has had a distinguished career in the pharmaceutical industry in positions such as Executive Director, Marketing and Sales, for Hoechst-Roussel and Chief Executive Officer of PanTherix. Most recently, he was Chief Executive Officer of Scottish Health Innovations Ltd., a newly formed company established to capture and exploit technology from the UK National Health Service.

Dr. Macdonald will be based in East Kilbride, Scotland, and will assume his new duties in July 2007.

Denny Willson, president and CEO of Cytokine PharmaSciences, stated: "Cameron is an excellent fit for us. He has broad experience in both large and small pharmaceutical companies and superb academic credentials. He also demonstrates a passion for building companies. We are delighted to bring him on board and look forward to creating a new and vibrant era at CTS".

Cytokine PharmaSciences, Inc. is a specialty pharmaceutical company engaged in developing and manufacturing controlled-release drug delivery products, with a strong focus in the area of women's health. Headquartered in King of Prussia (near Philadelphia), Pennsylvania, the company has a wholly owned subsidiary, Controlled Therapeutics (Scotland) limited, located in East Kilbride (near Glasgow), Scotland. CTS manufactures and supplies the company's successful cervical ripening product, the Cervidil® vaginal insert (Propess® in Europe and elsewhere). The company has three products in clinical development and employs 70 people at its locations in the U.S. and Scotland. For more information, please visit the company's websites at [www.cytokinepharmasciences.com](http://www.cytokinepharmasciences.com) and [www.ctscotland.com](http://www.ctscotland.com).